| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
3-O-Methylquercetin targets phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4), enzymes that hydrolyze cyclic AMP (cAMP) and cyclic GMP (cGMP). The compound is a selective and competitive inhibitor of PDE3 and PDE4. It inhibits cAMP-PDE with an IC50 of 13.8 μM and cGMP-PDE with an IC50 of 14.3 μM. By inhibiting PDE3 and PDE4, the compound increases intracellular cAMP and cGMP levels, leading to bronchodilation and anti-inflammatory effects. 3-O-Methylquercetin also modulates NF-κB and PI3K/Akt signaling pathways, contributing to its broader biological activities.
|
|---|---|
| ln Vitro |
3-O-Methylquercetin demonstrates in vitro inhibition of cAMP-PDE and cGMP-PDE with IC50 values of 13.8 μM and 14.3 μM, respectively. The compound is a selective and competitive PDE3/PDE4 inhibitor. It has anti-inflammatory effects and bronchodilating activity. 3-O-Methylquercetin modulates NF-κB and PI3K/Akt signaling pathways, regulates apoptosis, and protects against oxidative stress. These in vitro findings support the compound's potential for treating asthma and other inflammatory diseases.
|
| ln Vivo |
In vivo activity data for 3-O-Methylquercetin are not extensively documented. The compound has been studied for potential use in the treatment of asthma at doses that do not affect blood pressure, suggesting that it has been evaluated in vivo. Its bronchodilating and anti-inflammatory effects support potential efficacy in animal models of asthma or other inflammatory diseases. Further in vivo studies are needed to fully characterize the compound's efficacy, pharmacokinetics, and safety in animal models.
|
| Enzyme Assay |
The in vitro enzyme assay for 3-O-Methylquercetin involves measuring its inhibition of PDE3 and PDE4 enzymatic activities. Recombinant human PDE3 and PDE4 are expressed and purified. Enzyme activity is assessed by measuring the hydrolysis of cAMP or cGMP to AMP or GMP using a scintillation proximity assay or fluorescence polarization. 3-O-Methylquercetin is incubated with the enzyme and substrate at various concentrations. IC50 values are determined by fitting the inhibition data to a dose-response curve. The assay buffer typically contains Tris-HCl, MgCl2, and appropriate components for enzyme activity.
|
| Cell Assay |
In vitro cellular assays for 3-O-Methylquercetin typically use cell lines to assess anti-inflammatory and bronchodilating effects. Cells are treated with 3-O-Methylquercetin at various concentrations and stimulated with pro-inflammatory stimuli. Intracellular cAMP and cGMP levels are measured using ELISA. Pro-inflammatory cytokine production is measured by ELISA. The compound's ability to modulate signaling pathways such as NF-κB and PI3K/Akt can be assessed by Western blot. These assays confirm the compound's cellular activity.
|
| Animal Protocol |
In vivo animal experiments for 3-O-Methylquercetin would typically use animal models of asthma or other inflammatory diseases. The compound would be administered via oral or parenteral routes. Airway function, inflammatory markers in bronchoalveolar lavage fluid, and lung histology would be assessed. The compound's effects on blood pressure would be monitored. Further studies are needed to fully characterize the compound's in vivo efficacy and safety.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 3-O-Methylquercetin are not extensively documented. As a flavonoid with a molecular weight of 316.26, the compound is expected to have moderate bioavailability. Its solubility and metabolic stability may be influenced by its flavonoid structure. Further pharmacokinetic studies, including assessments of absorption, distribution, metabolism, and excretion (ADME), are necessary to fully characterize its PK profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3-O-Methylquercetin are not extensively available. As a natural flavonoid isolated from plants, the compound is generally considered to have a favorable safety profile. It has been studied for potential use in asthma treatment at doses that do not affect blood pressure, suggesting acceptable tolerability. Standard cytotoxicity assays may have been performed to assess safety. Further toxicological studies would be required for clinical development.
|
| References | |
| Additional Infomation |
3',4',5,7-Tetrahydroxy-3-methoxyflavone is a tetrahydroxyflavone with 4-hydroxy groups at the 3', 4', 5, and 7 positions, and a methoxy group at the 2 position. It is a metabolite and an antibacterial agent. It is both a tetrahydroxyflavone and a monomethoxyflavone. Its function is related to quercetin. It is the conjugate acid of 3',4',5-trihydroxy-3-methoxyflavone-7-ol salt. 3-O-methylquercetin has been reported in Artemisia incanescens, Haloxylon ammodendron, and other organisms with relevant data. See also: Tobacco (partial); Isorhamnetin (note moved here).
3-O-Methylquercetin is a flavonoid that selectively and competitively inhibits PDE3 and PDE4, with IC50 values of 13.8 μM for cAMP-PDE and 14.3 μM for cGMP-PDE. It has anti-inflammatory and bronchodilating effects and has been studied for asthma treatment. The compound modulates NF-κB and PI3K/Akt signaling, regulates apoptosis, and protects against oxidative stress. It has a molecular weight of 316.26. No clinical trials or regulatory approvals have been reported. |
| Molecular Formula |
C16H12O7
|
|---|---|
| Molecular Weight |
316.26
|
| Exact Mass |
316.058
|
| CAS # |
1486-70-0
|
| PubChem CID |
5280681
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
643.0±55.0 °C at 760 mmHg
|
| Flash Point |
244.7±25.0 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.762
|
| LogP |
2.02
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
23
|
| Complexity |
503
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC(=C(C=C3)O)O
|
| InChi Key |
WEPBGSIAWZTEJR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O7/c1-22-16-14(21)13-11(20)5-8(17)6-12(13)23-15(16)7-2-3-9(18)10(19)4-7/h2-6,17-20H,1H3
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-methoxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (158.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 0.62 mg/mL (1.96 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 6.2 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 0.62 mg/mL (1.96 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 6.2 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 0.62 mg/mL (1.96 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1620 mL | 15.8098 mL | 31.6196 mL | |
| 5 mM | 0.6324 mL | 3.1620 mL | 6.3239 mL | |
| 10 mM | 0.3162 mL | 1.5810 mL | 3.1620 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
